Document investigator qualifications, training records, financial disclosures, delegation logs, and site capability assessments required before trial initiation.
The site qualification visit
Dr. Katherine Okonkwo, Senior Clinical Research Associate at Meridian Pharmaceuticals, pushed open the glass doors of Lakeshore Regional Medical Center in Minneapolis, Minnesota, at precisely 8:55 AM on a Tuesday in early February. The snow had been falling since midnight, and her flight from Philadelphia had nearly been cancelled. But site qualification visits do not reschedule easily, and Dr. Elena Vasquez, the prospective principal investigator for the ASPIRE-3 diabetes trial, had cleared her entire morning.
Document investigator qualifications, training records, financial disclosures, delegation logs, and site capability assessments required before trial initiation.
The site qualification visit
Dr. Katherine Okonkwo, Senior Clinical Research Associate at Meridian Pharmaceuticals, pushed open the glass doors of Lakeshore Regional Medical Center in Minneapolis, Minnesota, at precisely 8:55 AM on a Tuesday in early February. The snow had been falling since midnight, and her flight from Philadelphia had nearly been cancelled. But site qualification visits do not reschedule easily, and Dr. Elena Vasquez, the prospective principal investigator for the ASPIRE-3 diabetes trial, had cleared her entire morning.
Katherine had reviewed Dr. Vasquez's CV the week before. Endocrinologist. Board certified. Fifteen years of clinical experience. Six prior clinical trials as principal investigator. On paper, an excellent candidate. But Katherine had learned long ago that credentials on paper and qualifications for a specific trial were not the same thing.
"Before we tour the clinic," Katherine said, settling into a chair in Dr. Vasquez's office, "I would like to review your documentation. May I see your current CV, your medical license, your GCP training certificate, and the CVs for any sub-investigators you plan to delegate to?"
Dr. Vasquez opened a manila folder. "I have my CV here. It was updated last month."
"Signed and dated?"
Dr. Vasquez paused. "I signed it, but I do not believe I dated it."
Katherine made a note. "And your GCP training?"
"I completed a course three years ago. I should have the certificate somewhere."
"Three years ago. Do you know if that training addressed ICH E6(R3), which was finalized last year?"
Dr. Vasquez's expression shifted. She was beginning to understand that qualification documentation was not a formality to be assembled hastily before a visit. It was evidence that would be scrutinized by monitors, auditors, and inspectors for years after the trial concluded.
"Perhaps," Katherine said gently, "we should start with what documentation you will need and why it matters. Then we can identify what needs to be updated before site activation."
This lesson is about the documents Katherine was asking to see. Before a single participant can be enrolled at any investigational site, the sponsor must have documented evidence that the investigator is qualified, that the site has appropriate capabilities, that delegation of responsibilities is clearly defined, and that financial relationships have been disclosed. These are not bureaucratic formalities. They are the foundation upon which the credibility of every data point from that site will rest.
What you will learn
By the end of this lesson, you will be able to:
Identify the essential qualification documents required for investigators and sub-investigators before trial initiation
Explain the specific requirements for investigator CVs, including currency, signature, and content expectations
Describe the purpose and content of FDA Form 1572 and its role in documenting investigator commitments
Discuss financial disclosure requirements under 21 CFR Part 54 and the documentation necessary to demonstrate compliance
Create and maintain delegation logs that meet regulatory expectations for clarity and specificity
Evaluate training documentation for completeness and relevance to specific trial responsibilities
Assess site capability documentation and understand its role in site selection decisions
Let me be direct about something: I have observed more inspection findings related to qualification documentation than to almost any other category of essential documents. The irony is that these documents are relatively straightforward to prepare correctly. The failures typically stem not from complexity but from inattention, from treating qualification as a checkbox exercise rather than as the serious evidentiary matter it is.
Katherine had reviewed Dr. Vasquez's CV the week before. Endocrinologist. Board certified. Fifteen years of clinical experience. Six prior clinical trials as principal investigator. On paper, an excellent candidate. But Katherine had learned long ago that credentials on paper and qualifications for a specific trial were not the same thing.
"Before we tour the clinic," Katherine said, settling into a chair in Dr. Vasquez's office, "I would like to review your documentation. May I see your current CV, your medical license, your GCP training certificate, and the CVs for any sub-investigators you plan to delegate to?"
Dr. Vasquez opened a manila folder. "I have my CV here. It was updated last month."
"Signed and dated?"
Dr. Vasquez paused. "I signed it, but I do not believe I dated it."
Katherine made a note. "And your GCP training?"
"I completed a course three years ago. I should have the certificate somewhere."
"Three years ago. Do you know if that training addressed ICH E6(R3), which was finalized last year?"
Dr. Vasquez's expression shifted. She was beginning to understand that qualification documentation was not a formality to be assembled hastily before a visit. It was evidence that would be scrutinized by monitors, auditors, and inspectors for years after the trial concluded.
"Perhaps," Katherine said gently, "we should start with what documentation you will need and why it matters. Then we can identify what needs to be updated before site activation."
This lesson is about the documents Katherine was asking to see. Before a single participant can be enrolled at any investigational site, the sponsor must have documented evidence that the investigator is qualified, that the site has appropriate capabilities, that delegation of responsibilities is clearly defined, and that financial relationships have been disclosed. These are not bureaucratic formalities. They are the foundation upon which the credibility of every data point from that site will rest.
What you will learn
By the end of this lesson, you will be able to:
Identify the essential qualification documents required for investigators and sub-investigators before trial initiation
Explain the specific requirements for investigator CVs, including currency, signature, and content expectations
Describe the purpose and content of FDA Form 1572 and its role in documenting investigator commitments
Discuss financial disclosure requirements under 21 CFR Part 54 and the documentation necessary to demonstrate compliance
Create and maintain delegation logs that meet regulatory expectations for clarity and specificity
Evaluate training documentation for completeness and relevance to specific trial responsibilities
Assess site capability documentation and understand its role in site selection decisions
Let me be direct about something: I have observed more inspection findings related to qualification documentation than to almost any other category of essential documents. The irony is that these documents are relatively straightforward to prepare correctly. The failures typically stem not from complexity but from inattention, from treating qualification as a checkbox exercise rather than as the serious evidentiary matter it is.